EMA Stands By Recommendation To Suspend Modified-Release Paracetamol From Market
Executive Summary
The EMA’s drug safety committee has re-examined its recommendation in September to suspend modified-release paracetamol at the request of two companies that sell such products.
You may also be interested in...
Contraception Advice Relaxed For Mycophenolate In EU, Modified-Release Paracetamol Suspension Confirmed
The EMA has relaxed its recommendations on the use of contraception in people taking the immunosuppressant, mycophenolate, but continues to stress the importance of avoiding pregnancy in women taking the drug. In another safety-related announcement, EU member states have agreed that products containing modified-release paracetamol should be suspended.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.